Tags: drug | Pfizer | cancer | studies

Pfizer Says Lung Cancer Drug Fails Two Late-Stage Studies

Monday, 27 Jan 2014 10:52 AM

Pfizer Inc. said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients who received prior treatment for advanced non-small cell lung cancer.

The company said patients given the drug, dacomitinib, did not show improved survival without the cancer worsening, compared with another non-small cell lung cancer drug.

The patients in this trial, dubbed Archer 1009, were previously treated with chemotherapy.

In the second study, Pfizer said the overall survival of patients taking the drug was not prolonged when compared with patients given a placebo.

Patients in this trial, named BR.26, had failed chemotherapy as well as a form of treatment that slows down or stops the growth of cancer-causing cells.

The company said the adverse events reported with the drug's use in both trials were consistent with its safety profile.

Pfizer said the drug is also being tested in a third late-stage trial on patients with advanced non-small cell lung cancer who have not received prior treatment. The results from the study are expected in 2015.

Dacomitinib is also being tested to treat pancreatic cancer, colorectal cancer and a form of cancer that affects the head and neck.

Shares of the company closed at $30.09 Friday on the New York Stock Exchange. The stock was little changed at $30.11 in premarket trading on Monday.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Pfizer Inc. said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients who received prior treatment for advanced non-small cell lung cancer.
drug,Pfizer,cancer,studies
221
2014-52-27
Monday, 27 Jan 2014 10:52 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved